156 related articles for article (PubMed ID: 34988585)
1. Combined treatment with anti-HER2/neu and anti-4-1BB monoclonal antibodies induces a synergistic antitumor effect but requires dose optimization to maintain immune memory for protection from lethal rechallenge.
Kim HY; Choi JH; Haque MM; Park JH; Kim IH; Choi BK; Lee A; Park S
Cancer Immunol Immunother; 2022 Apr; 71(4):967-978. PubMed ID: 34988585
[TBL] [Abstract][Full Text] [Related]
2. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.
Song H; Kim TO; Ma SY; Park JH; Choi JH; Kim JH; Kang MS; Bae SK; Kim KH; Kim TH; Seo SK; Choi IW; Song GA; Mortenson ED; Fu YX; Park S
BMC Cancer; 2014 Sep; 14():647. PubMed ID: 25179116
[TBL] [Abstract][Full Text] [Related]
4. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
[TBL] [Abstract][Full Text] [Related]
5. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
[TBL] [Abstract][Full Text] [Related]
6. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
[TBL] [Abstract][Full Text] [Related]
7. A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.
Mardiana S; John LB; Henderson MA; Slaney CY; von Scheidt B; Giuffrida L; Davenport AJ; Trapani JA; Neeson PJ; Loi S; Haynes NM; Kershaw MH; Beavis PA; Darcy PK
Cancer Res; 2017 Mar; 77(6):1296-1309. PubMed ID: 28082401
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of rat-neu
Sow HS; Benonisson H; Brouwers C; Linssen MM; Camps M; Breukel C; Claassens J; van Hall T; Ossendorp F; Fransen MF; Verbeek JS
Sci Rep; 2020 Mar; 10(1):3933. PubMed ID: 32127568
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice.
Lin GH; Liu Y; Ambagala T; Kwon BS; Ohashi PS; Watts TH
PLoS One; 2010 Jun; 5(6):e11003. PubMed ID: 20543982
[TBL] [Abstract][Full Text] [Related]
10. Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors.
Gao Y; Whitaker-Dowling P; Griffin JA; Barmada MA; Bergman I
Cancer Gene Ther; 2009 Jan; 16(1):44-52. PubMed ID: 18654610
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice.
Cuadros C; Dominguez AL; Lollini PL; Croft M; Mittler RS; Borgström P; Lustgarten J
Int J Cancer; 2005 Oct; 116(6):934-43. PubMed ID: 15856473
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy.
Kim YH; Choi BK; Oh HS; Kang WJ; Mittler RS; Kwon BS
Mol Cancer Ther; 2009 Feb; 8(2):469-78. PubMed ID: 19190115
[TBL] [Abstract][Full Text] [Related]
13. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
May KF; Chen L; Zheng P; Liu Y
Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
Buchan SL; Dou L; Remer M; Booth SG; Dunn SN; Lai C; Semmrich M; Teige I; Mårtensson L; Penfold CA; Chan HTC; Willoughby JE; Mockridge CI; Dahal LN; Cleary KLS; James S; Rogel A; Kannisto P; Jernetz M; Williams EL; Healy E; Verbeek JS; Johnson PWM; Frendéus B; Cragg MS; Glennie MJ; Gray JC; Al-Shamkhani A; Beers SA
Immunity; 2018 Nov; 49(5):958-970.e7. PubMed ID: 30446386
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma.
McKee SJ; Doff BL; Soon MS; Mattarollo SR
Cancer Immunol Res; 2017 Mar; 5(3):191-197. PubMed ID: 28115358
[TBL] [Abstract][Full Text] [Related]
16. Marked expansion of CD11c+CD8+ T-cells in melanoma-bearing mice induced by anti-4-1BB monoclonal antibody.
Ju SA; Park SM; Lee SC; Kwon BS; Kim BS
Mol Cells; 2007 Aug; 24(1):132-8. PubMed ID: 17846508
[TBL] [Abstract][Full Text] [Related]
17. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
18. Molecular and metabolic pathways mediating curative treatment of a non-Hodgkin B cell lymphoma by Sindbis viral vectors and anti-4-1BB monoclonal antibody.
Yu M; Scherwitzl I; Opp S; Tsirigos A; Meruelo D
J Immunother Cancer; 2019 Jul; 7(1):185. PubMed ID: 31307539
[TBL] [Abstract][Full Text] [Related]
19. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C
Front Immunol; 2020; 11():577. PubMed ID: 32391001
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer.
Li Q; Iuchi T; Jure-Kunkel MN; Chang AE
Int J Biol Sci; 2007 Nov; 3(7):455-62. PubMed ID: 18071585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
